Bank of India Multi Asset Allocation Fund
The scheme seek to long term capital growth by predominantly investing in equity and equity related securities, debt & money market instruments and Gold ETF/ Silver ETF.
Growthvine rating: 1/5 — ranked #40 of 48 in category.
Fund basics
| Category | Hybrid: Multi Asset |
|---|
| NAV | ₹12.96 (as of 2026-08-21) |
|---|
| AUM | ₹365 Cr |
|---|
| Expense ratio | 1.74% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Nilesh Jethani |
|---|
| Exit load | For units in excess of 10% of the investment, 1% will be charged for redemption within 3 months |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | -9.57% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 92.2% of NIFTY Multi Asset - Equity : Debt : Arbitrage : REITs/InvITs (50:20:20:10) Index's upside and 66.7% of its downside.
Market cap allocation
| Large cap | 35.5% |
|---|
| Mid cap | 33.3% |
|---|
| Small cap | 31.1% |
|---|
Concentration
| Top 5 holdings | 19.9% |
|---|
| Top 10 holdings | 33.4% |
|---|
| Total holdings | 61 |
|---|
Top holdings
- HDFC Bank Ltd. — 5.8%
- TREPS — 5.7%
- Reliance Industries Ltd — 4.4%
- Dixon Technologies (India) Limited — 3.5%
- Aurobindo Pharma Ltd. — 3.2%
- FSN E-Commerce Ventures Limited — 3.0%
- Stylam Industries Limited — 2.9%
- TIPS MUSIC LIMITED — 2.8%
- Kotak Mahindra Bank Ltd. — 2.7%
- Entero Healthcare Solutions Limited — 2.6%
Top sectors
- Banking & Financial — 13.4%
- Pharma & Biotech — 11.6%
- Retail — 8.1%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 8.0% | Q1 (Top) | #3 of 44 |
| 2025 | 10.2% | Q4 (Bottom) | #31 of 34 |